Table 7.
Area under curve (AUC) calculations of oral CBD UltraShear Nanoemulsion 5 mg/rat results at 24 h
| CBD AUC | Relative bioavailability, % | CBD-7-COOH (CBD equivalents) AUC | 7-OH-CBD (CBD equivalents) AUC | TOTAL CBD equivalents AUC | Relative total absorption, % | |
|---|---|---|---|---|---|---|
| Rat 1 | 1,073.9 | 27.9 | 4,964.0 | 474.0 | 6,512.0 | 83.4 |
| Rat 2 | 657.9 | 17.1 | 4,105.7 | 256.7 | 5,020.3 | 64.3 |
| Rat 3 | 584.5 | 15.2 | 6,254.0 | 321.5 | 7,159.9 | 91.7 |
| Rat 4 | 1,586.1 | 41.3 | 4,246.5 | 355.5 | 6,188.0 | 79.3 |
| Avg (n = 4) | 975.6 | 25.4 | 4,892.6 | 351.9 | 6,220.0 | 79.7 |
| Std Dev | 398.8 | 10.4 | 850.7 | 78.9 | 776.0 | 9.9 |
Relative bioavailability of CBD from oral-GI UltraShear nanoemulsion (F(OGI/IV)) after 1st pass metabolism. Relative total absorption of CBD equivalents from oral-GI UltraShear nanoemulsion (A(OGI/IV)) includes metabolites after 1st pass metabolism.